Buy Shafaa Evolve Magic Mushroom Microdosing Prime Capsules
Shafaa means healing. Evolve your brain, power up your memory, and boost your cognition back-end with Shafaa Evolve Magic Mushroom Microdosing Prime Capsules!
These sub-perceptional and non-psychoactive capsules consist of pure Golden Teacher Psilocybe Cubensis and are carefully produced for easier digestion of microdose psilocybin mushrooms. These vegan microdosing prime capsules are packed in a small, convenient, resealable, and easy-to-travel pouch for those with an on-the-go and capacity-maximizing lifestyle.
Microdosing psychedelic mushrooms require an accurate regimen and self-monitoring protocol. There are several protocols available out there, proposed by psychedelic gurus like Paul Stamets, James Fadiman, Paul Austin’s Ultimate Guide to Microdosing Psychedelics, etc.
Each bottle consists of 25 capsules (100mg of shrooms).
- Enhance your mood, and clarity, and boost creativity with these simple and tasteless capsules
- Customizable and easy-to-regulate dosage
- Each capsule contains 100 mg (0.1g) of dried magic mushrooms
- Non-GMO, Preservative Free, Kosher & Halal Certified, gluten-free natural gelatin vegan capsules
|Psilocybe Cubensis (Golden Teacher)||100 mg|
The benefits of full-dose psychedelics
While more than a thousand early studies linked psychedelic use with beneficial effects , there was a 40-year pause in psychedelic research following the prohibition of these substances . Despite the continued prohibition, modern research has revealed the promising potential of LSD and psilocybin for treating alcohol and tobacco dependence [depression, and end-of-life anxiety [20,21,22], while related research on 3,4-methylenedioxymethamphetamine (MDMA) has shown great promise for treating post-traumatic stress disorder . Psychedelics can also increase openness and occasion mystical-type experiences in healthy controls [24,25,26]. As full-dose psychedelics appear to aid in the relief of severe, chronic psychiatric conditions (e.g. depression, anxiety, PTSD), milder mental health concerns may plausibly be treated by lower, recurring doses. This is especially worth considering if certain full-dose outcomes are found to rely on purely pharmacologic mechanisms rather than primarily on phenomenological experiences .